Algert Global LLC Purchases New Position in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Algert Global LLC purchased a new stake in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 66,285 shares of the company's stock, valued at approximately $3,217,000. Algert Global LLC owned 0.14% of Amphastar Pharmaceuticals at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in the stock. GAMMA Investing LLC grew its stake in Amphastar Pharmaceuticals by 70.0% during the third quarter. GAMMA Investing LLC now owns 663 shares of the company's stock worth $32,000 after purchasing an additional 273 shares during the period. Innealta Capital LLC acquired a new stake in Amphastar Pharmaceuticals during the second quarter worth approximately $55,000. Blue Trust Inc. grew its stake in Amphastar Pharmaceuticals by 23.9% during the second quarter. Blue Trust Inc. now owns 1,604 shares of the company's stock worth $70,000 after purchasing an additional 309 shares during the period. Asset Management One Co. Ltd. acquired a new stake in Amphastar Pharmaceuticals during the third quarter worth approximately $78,000. Finally, Mirae Asset Global Investments Co. Ltd. grew its stake in Amphastar Pharmaceuticals by 20.6% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,761 shares of the company's stock worth $85,000 after purchasing an additional 301 shares during the period. Institutional investors and hedge funds own 65.09% of the company's stock.

Insider Activity

In related news, Director Richard K. Prins sold 5,000 shares of Amphastar Pharmaceuticals stock in a transaction on Tuesday, November 12th. The stock was sold at an average price of $48.80, for a total transaction of $244,000.00. Following the completion of the sale, the director now owns 31,471 shares of the company's stock, valued at approximately $1,535,784.80. This trade represents a 13.71 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Floyd F. Petersen sold 3,000 shares of Amphastar Pharmaceuticals stock in a transaction dated Thursday, September 5th. The stock was sold at an average price of $46.47, for a total value of $139,410.00. Following the sale, the director now directly owns 75,409 shares of the company's stock, valued at approximately $3,504,256.23. This trade represents a 3.83 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 27,533 shares of company stock worth $1,378,252. 27.10% of the stock is owned by corporate insiders.

Amphastar Pharmaceuticals Stock Performance

NASDAQ:AMPH traded down $0.42 during trading hours on Tuesday, reaching $44.22. The stock had a trading volume of 283,613 shares, compared to its average volume of 398,680. The company has a debt-to-equity ratio of 0.82, a quick ratio of 2.61 and a current ratio of 3.43. The stock has a 50 day simple moving average of $48.19 and a 200 day simple moving average of $44.48. Amphastar Pharmaceuticals, Inc. has a 12-month low of $36.56 and a 12-month high of $65.92. The stock has a market cap of $2.13 billion, a P/E ratio of 14.88, a price-to-earnings-growth ratio of 0.90 and a beta of 0.82.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on AMPH shares. Wells Fargo & Company started coverage on Amphastar Pharmaceuticals in a research note on Friday. They set an "equal weight" rating and a $55.00 target price for the company. Needham & Company LLC reiterated a "hold" rating on shares of Amphastar Pharmaceuticals in a report on Thursday, August 8th. Piper Sandler cut their price target on Amphastar Pharmaceuticals from $71.00 to $66.00 and set an "overweight" rating on the stock in a report on Thursday, August 8th. Finally, StockNews.com lowered Amphastar Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Friday, November 1st. Three investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus price target of $60.33.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.